Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 18Neoplasm Metastasis 14Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Recurrence 9Ovarian Neoplasms 7Skin Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Renal Cell 5Carcinoma, Basal Cell 5Triple Negative Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Merkel Cell 3Adenocarcinoma 3Sarcoma 2Pancreatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Glioma 2

Interventions

cemiplimab 2S 1 (combination) 2zimberelimab 1sintilimab 1quemliclustat 1pembrolizumab 1lorlatinib 1fludarabine 1WW Domain-Containing Oxidoreductase 1Pemetrexed 1Interleukin-2 1Drug Therapy 1Docetaxel 1Cyclophosphamide 1Cisplatin 1Cetuximab 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-Small Cell Lung Cancer × cemiplimab × Clear all
NCT05557591 2026-05-06

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
51 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT05785767 2026-01-22

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Regeneron Pharmaceuticals

Phase 2/3 Active not recruiting
850 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡